PHAXIAM Therapeutics 将来の成長

Future 基準チェック /26

PHAXIAM Therapeuticsの収益は年間3.5%で減少すると予測されていますが、年間収益は年間92.4%で増加すると予想されています。EPS は年間1.7%で減少すると予想されています。

主要情報

-3.5%

収益成長率

-1.7%

EPS成長率

Biotechs 収益成長	4.6%
収益成長率	92.4%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	14 Nov 2024

今後の成長に関する最新情報

Recent updates

業績と収益の成長予測

ENXTPA:PHXM - アナリストの将来予測と過去の財務データ ( )EUR Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	13	-19	-39	N/A	2
12/31/2025	2	-32	-33	N/A	2
12/31/2024	1	-25	-29	N/A	2
6/30/2024	2	-22	N/A	N/A	N/A
3/31/2024	2	-23	N/A	N/A	N/A
12/31/2023	1	-23	-25	-24	N/A
9/30/2023	6	-12	N/A	N/A	N/A
6/30/2023	6	-11	-23	-23	N/A
3/31/2023	6	6	N/A	N/A	N/A
12/31/2022	7	0	-32	-32	N/A
9/30/2022	2	-18	N/A	N/A	N/A
6/30/2022	3	-27	-45	-45	N/A
3/31/2022	3	-54	N/A	N/A	N/A
12/31/2021	4	-54	-57	-57	N/A
9/30/2021	4	-61	N/A	N/A	N/A
6/30/2021	4	-66	-55	-55	N/A
3/31/2021	4	-68	N/A	N/A	N/A
12/31/2020	4	-73	-53	-52	N/A
9/30/2020	4	-73	N/A	N/A	N/A
6/30/2020	4	-68	-52	-49	N/A
3/31/2020	5	-69	N/A	N/A	N/A
12/31/2019	5	-63	-63	-43	N/A
9/30/2019	6	-52	-69	-38	N/A
6/30/2019	5	-49	-73	-52	N/A
3/31/2019	4	-38	N/A	N/A	N/A
12/31/2018	4	-38	-53	-48	N/A
9/30/2018	3	-42	N/A	N/A	N/A
6/30/2018	4	-38	-33	-31	N/A
3/31/2018	3	-39	N/A	N/A	N/A
12/31/2017	3	-34	N/A	-25	N/A
9/30/2017	4	-27	N/A	N/A	N/A
6/30/2017	4	-26	N/A	-23	N/A
3/31/2017	5	-24	N/A	N/A	N/A
12/31/2016	4	-22	N/A	-18	N/A
9/30/2016	4	-20	N/A	-17	N/A
6/30/2016	4	-19	N/A	-17	N/A
3/31/2016	3	-16	N/A	N/A	N/A
12/31/2015	3	-15	N/A	-15	N/A
9/30/2015	3	-14	N/A	-12	N/A
6/30/2015	2	-12	N/A	-10	N/A
3/31/2015	2	-11	N/A	-9	N/A
12/31/2014	2	-9	N/A	-7	N/A
9/30/2014	2	-8	N/A	-7	N/A
6/30/2014	2	-7	N/A	-6	N/A
3/31/2014	2	-8	N/A	-6	N/A
12/31/2013	2	-8	N/A	-6	N/A

アナリストによる今後の成長予測

収入対貯蓄率: PHXM今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: PHXM今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: PHXM今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: PHXMの収益 ( 92.4% ) French市場 ( 5.6% ) よりも速いペースで成長すると予測されています。

高い収益成長: PHXMの収益 ( 92.4% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: PHXMの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

PHAXIAM Therapeutics 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

No longer forecast to breakeven

No longer forecast to breakeven

Price target decreased to €5.80

No longer forecast to breakeven

Consensus forecasts updated

Consensus forecasts updated

Recent updates

PHAXIAM Therapeutics Receives FDA Clearance to Initiate Phase II GLORIA Study in U.S

PHAXIAM Therapeutics Announces the Validation of a New Investigator-Initiated Phase 2 Study

PHAXIAM Therapeutics Announces Enrolment of First Patient in the Phase 1 Study for the Treatment of Endocarditis Infections Caused by Staphylococcus Aureus

PHAXIAM Therapeutics Announces Intention to Voluntary Delist ADS from Nasdaq Capital Market

PHAXIAM Therapeutics S.A. to Report Q3, 2024 Results on Nov 13, 2024

PHAXIAM Therapeutics Obtains Authorizations to Launch Its Phase 1 Study in Endocarditis Infections Caused by Staphylococcus Aureus

New major risk - Revenue and earnings growth

PHAXIAM Therapeutics Announces High Coverage Performance of Its Two Anti-Staphylococcus Aureus Phages over Clinical Strains

PHAXIAM Therapeutics Receives Compliance Notice from Nasdaq

New major risk - Financial position

PHAXIAM Therapeutics S.A. Announces Launch of New Preclinical Development

PHAXIAM Therapeutics S.A. to Report Q2, 2023 Results on Sep 21, 2023

New major risk - Shareholder dilution

ERYTECH Pharma S.A.(NasdaqCM:PHXM) dropped from NASDAQ Composite Index

ERYTECH Pharma S.A Announces Management Changes

Erytech Pharma S.A. Approves the Appointment of Robert Sebbag and Eric Leire as Directors

Akkadian Initiates Proceedings to Postpone the Vote on the Merger with Pherecydes

Mediobanca Banca di Credito Finanziario S.p.A. agreed to acquire an unknown minority stake in Anima Holding S.p.A. from Omnes Capital S.A.S., Auriga Partners, Ace Capital Partners, Go Capital SAS and Participations Besançon.

No longer forecast to breakeven

Insufficient new directors

ERYTECH Announces Receipt of Nasdaq Notice

ERYTECH Pharma S.A. to Report Q3, 2022 Results on Nov 21, 2022

ERYTECH Pharma to Stop Further Plans to Pursue A BLA Submission Seeking an Approval for Graspa® in Hypersensitive ALL

Insufficient new directors

Insufficient new directors

No longer forecast to breakeven

Price target decreased to €5.80

Catalent, Inc. (NYSE:CTLT) acquired Cell therapy manufacturing facility in Princeton, New Jersey of ERYTECH Pharma S.A. (ENXTPA:ERYP) for $44.5 million.

Catalent, Inc. (NYSE:CTLT) entered into an asset purchase agreement to acquire Cell therapy manufacturing facility in Princeton, New Jersey of ERYTECH Pharma S.A. (ENXTPA:ERYP) for $44.5 million.

Catalent, Inc. (NYSE:CTLT) entered into an asset purchase agreement to acquire Cell therapy manufacturing facility in Princeton, New Jersey of ERYTECH Pharma S.A. (ENXTPA:ERYP) for $44.5 million.

ERYTECH Pharma Announces Publication of Positive Results from Eryaspase Phase 2 Trial

ERYTECH Pharma Expands Patent Portfolio for the Treatment of Rare Metabolic Diseases

ERYTECH Pharma Announces Presentation of Results of Two Clinical Trials of Eryaspase in Pancreatic Cancer at ASCO GI

No longer forecast to breakeven

Consensus forecasts updated

Consensus forecasts updated

Consensus forecasts updated

Analysts Expect Breakeven For ERYTECH Pharma S.A. (EPA:ERYP) Before Long

Price target decreased to €14.50

Consensus forecasts updated

Is ERYTECH Pharma (EPA:ERYP) Using Debt In A Risky Way?

Analysts update estimates

Earnings beat expectations, revenue disappoints

New 90-day low: €6.63

ERYTECH Pharma Announces TRYbeCA-1 Phase 3 Trial in 2L Pancreatic Cancer to Continue to Final Analysis

ERYTECH Pharma's (EPA:ERYP) Stock Price Has Reduced 60% In The Past Five Years

New 90-day high: €8.88

ERYTECH Pharma Announces First Patient Enrolled in a Phase 1 Investigator Sponsored Trial of Eryaspase in First-Line Pancreatic Cancer

ERYTECH Completes Enrollment in TRYbeCA-1 Phase 3 Trial in Second-Line Pancreatic Cancer

ERYTECH Pharma (EPA:ERYP) Has Debt But No Earnings; Should You Worry?

New 90-day high: €8.02

New 90-day high: €6.50

Analysts update estimates

Revenue misses expectations

ERYTECH Pharma S.A. Announces That an Abstract Detailing Results from the NOPHO Sponsored Phase 2 Trial of Eryaspase in All Patients, Has Been Selected for Oral Presentation At the Upcoming 62nd American Society of Hematology (ASH) Annual Meeting

New 90-day low: €4.24

ERYTECH Pharma S.A. to Report Q2, 2021 Results on Sep 20, 2021

ERYTECH Pharma Appoints Stewart Craig as Chief Technical Officer and Member of the Executive Team

New 90-day low: €4.95

New 90-day low - €5.51

New 90-day low - €6.06

New 90-day low - €6.74

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘